Table 4.
Subgroup analysis of triglycerides levels with mortality
| Number | All-cause mortality HR (95% CI) P-value |
P for log likelihood ratio test | Cardiovascular disease mortality HR (95% CI) P-value |
P for log likelihood ratio test | |||
|---|---|---|---|---|---|---|---|
| Cutoff value, mmol/L | < 1.52 | ≥ 1.52 | < 1.10 | ≥ 1.10 | |||
| Age, years | |||||||
| ≥ 65 | 2502 | 0.78 (0.60, 1.01) 0.0558 | 1.09 (0.99, 1.19) 0.0654 | 0.024 | 0.54 (0.19, 1.51) 0.2400 | 1.00 (0.84, 1.19) 0.9968 | 0.267 |
| < 65 | 9135 | 1.21 (0.87, 1.68) 0.2640 | 1.05 (0.95, 1.15) 0.3327 | 0.436 | 1.49 (0.30, 7.35) 0.6273 | 1.15 (0.96, 1.38) 0.1206 | 0.757 |
| Gender | |||||||
| Male | 5659 | 0.91 (0.69, 1.19) 0.4874 | 1.14 (1.05, 1.23) 0.0016 | 0.136 | 0.85 (0.29, 2.50) 0.7651 | 1.21 (1.05, 1.40) 0.0096 | 0.527 |
| Female | 5978 | 0.89 (0.65, 1.22) 0.4596 | 1.08 (0.97, 1.20) 0.1491 | 0.277 | 0.44 (0.10, 2.00) 0.2873 | 0.92 (0.72, 1.18) 0.5239 | 0.367 |
| Body mass index, kg/m2 | |||||||
| ≥ 25 | 8102 | 0.90 (0.70, 1.16) 0.4312 | 1.11 (1.03, 1.19) 0.0036 | 0.143 | 0.70 (0.22, 2.19) 0.5437 | 1.09 (0.94, 1.26) 0.2783 | 0.471 |
| < 25 | 3535 | 0.78 (0.54, 1.12) 0.1821 | 1.23 (1.03, 1.47) 0.0244 | 0.050 | 0.43 (0.11, 1.67) 0.2241 | 1.44 (1.09, 1.90) 0.0095 | 0.105 |
| Race | |||||||
| Non-white | 6114 | 1.00 (0.74, 1.35) 0.9952 | 1.05 (0.96, 1.16) 0.2861 | 0.757 | 0.34 (0.10, 1.11) 0.0738 | 1.17 (0.98, 1.39) 0.0916 | 0.054 |
| White | 5523 | 0.79 (0.60, 1.05) 0.1088 | 1.16 (1.07, 1.27) 0.0007 | 0.016 | 1.08 (0.30, 3.96) 0.9055 | 1.07 (0.89, 1.27) 0.4852 | 0.982 |
| Lipid-lowering drugs | |||||||
| No | 10,251 | 0.91 (0.73, 1.15) 0.4476 | 1.12 (1.05, 1.20) 0.0015 | 0.114 | 0.53 (0.20, 1.42) 0.2078 | 1.14 (0.98, 1.32) 0.0813 | 0.147 |
| Yes | 1386 | 0.75 (0.48, 1.17) 0.2035 | 1.11 (0.96, 1.29) 0.1696 | 0.126 | 1.05 (0.16, 6.85) 0.9565 | 1.07 (0.83, 1.37) 0.6183 | 0.990 |
| Hypertension | |||||||
| No | 6779 | 0.87 (0.59, 1.29) 0.4962 | 1.07 (0.94, 1.23) 0.2792 | 0.350 | 2.16 (0.22, 21.49) 0.5106 | 0.95 (0.68, 1.34) 0.7752 | 0.483 |
| Yes | 4858 | 0.81 (0.64, 1.03) 0.0903 | 1.14 (1.06, 1.22) 0.0006 | 0.013 | 0.46 (0.18, 1.17) 0.1035 | 1.16 (1.01, 1.33) 0.0358 | 0.066 |
| Diabetes | |||||||
| No | 9867 | 0.90 (0.71, 1.14) 0.3882 | 1.14 (1.04, 1.25) 0.0065 | 0.101 | 0.85 (0.30, 2.43) 0.7648 | 0.91 (0.72, 1.14) 0.4063 | 0.911 |
| Yes | 1770 | 0.82 (0.55, 1.22) 0.3276 | 1.11 (1.01, 1.22) 0.0287 | 0.162 | 0.43 (0.09, 2.17) 0.3091 | 1.25 (1.07, 1.46) 0.0054 | 0.223 |
| CVD | |||||||
| No | 10,646 | 0.93 (0.74, 1.18) 0.5569 | 1.10 (1.02, 1.18) 0.0142 | 0.217 | 0.83 (0.28, 2.43) 0.7333 | 1.01 (0.85, 1.20) 0.8977 | 0.727 |
| Yes | 991 | 0.64 (0.42, 0.98) 0.0405 | 1.18 (1.04, 1.34) 0.0112 | 0.012 | 0.35 (0.07, 1.64) 0.1826 | 1.26 (1.04, 1.52) 0.0192 | 0.123 |
Notes: Multivariate Cox regression was performed to examine the association between triglyceride levels and mortality
Data are shown in HRs and 95%CI
HR hazard ratios; CI confidence intervals; CAD coronary heart disease
When analyzing a subgroup variable, age, gender, race, education level, smoking, body mass index, systolic blood pressure, estimated glomerular filtration rate, C-reactive protein, energy, total cholesterol, high density lipoprotein cholesterol, hypertension, diabetes, medicine use (antihypertensive drugs, hypoglycemic agents, lipid-lowering drugs, and antiplatelet drugs) were all adjusted except the variable itself